US20160031798A1

US20160031798A1 - 2-amino-3-methyl-hex-5-enoic acid and its use in the prodction of peptides such as bacitracins

Info

Publication number: US20160031798A1
Application number: US14/848,500
Authority: US
Inventors: Martin Mansson; Christine Senstad; Jon Efskind; Vidar Bjornstad
Original assignee: Xellia Pharmaceuticals ApS
Current assignee: Xellia Pharmaceuticals ApS
Priority date: 2009-10-28
Filing date: 2015-09-09
Publication date: 2016-02-04
Also published as: US9272983B2; PL2493843T3; PT2493843E; JP2013509366A; AU2010311760B2; HUE026747T2; WO2011051071A1; EP2493843A1; CN102596894B; KR20120093310A; HRP20160022T1; CN102596894A; CA2775631A1; SI2493843T1; RU2012120613A; RU2611006C2; JP5689892B2; ES2559934T3; IL219182A0; ZA201201835B

Abstract

The present invention concerns 2-amino-3-mmethyl-hex-5-enoic acid, its use for the production of peptides such as bacitracins and a method for producing it.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Ser. No. 13/502,144 filed on Apr. 16, 2012 which is a 371 of PCT/EP10/64511 filed on Sep. 30, 2010 which claims the benefit of priority to U.S. 61/255,521 filed on Oct. 28, 2009, are incorporated by reference herein in their entirety.

FIELD OF INVENTION

The present invention relates to new amino acid compounds.

BACKGROUND OF INVENTION

The majority of proteins are made of 20 different α-amino acids: Alanine, Arginine, Asparagine, Aspartic acid, Cysteine, Glutamine, Glutamate, Phenytalanine, Glycine Histidine, Isoleucine, Lysine, Leucine, Methionine, Proline, Serine, Threonine, Tryptophan, Tyrosine and Valine.
However, there are many biologically active peptides comprising other amino acids such as: Homocysteine, Ornithine, 4-Hydroxyproline, 5-Hydroxylysine, Selenocysteine, Formylmethionin, Phosphoserine, Acetylserine, Methylarginine etc.
Amino acids in D-configuration are common in non-ribosomally synthesized bacterial peptides and less common in ribosomally synthesized proteins. For example in the non-ribosomally synthesized Bacitracins, the amino acid residues in position 4, 7, 9 and 11 are usually in D-configuration (Glu, Orn, Phe and Asp).
Bacitracins are peptide antibiotics naturally produced by Bacillus subtilis and Bacillus licheniformis. Several Bacitracins have been identified of which Bacitracin A is of primary importance and is highly active (Biochemistry, vol. 39 no 14, 2000, page 4037-45 by Epperson and Ming). The primary structure of Bacitracin A is NH₂-L-Ile₁-L-Thiazoline₂-L-Leu₃-D-Glu₄-L-Ile₅-L-Lys₆-D-Orn₇-L-Ile₈-D-Phe₉-L-His₁₀- D-Asp₁₁-L-Asn₁₂-COOH which is cyclized between the ε-amino group of L-Lys₆and the R-carboxyl group of L-Asn₁₂.

PRIOR ART

Several non-ribosomally synthesized peptides comprise unusual amino acids. For example cyclosporin A comprises 2(S)-amino-3(10-hydroxy-4(R)-methyl-6(E)-octenoic acid which is crucial for binding to the intracellular receptor for cyclophilin, and thus for its immunosuppressive activity (Journal of Biological Chemistry, vol. 268 no 35, 1993 by Offenzeller et al.).
Several uncommon amino acids resemble the structure of Isoleucine:
2-Amino-5-methyl-5-hexenoic acid, a new methionine analog, was isolated from a fermentation broth of Streptomyces (Journal of Antibiotics vol. 32 no. 11, page 1118-1124, 1979 by Takeuchi et al).
4 methylene-norleucine and 2-aminohept-6-enoic acid are compounds with the formula: C₇H₁₃NO₂.
4 methyl-norleucine is an isoleucine derivative which can be incorporated into a recombinant protein. (J Pharm Biomed Anal, vol 31. no. 5, 2003, page 979-987 by Muramatsu et al).
2-amino-3-methyl-4-pentenoic acid is an unsaturated isoleucine analogue which can be incorporated into proteins (Chembiochem vol. 7 no. 1, 2006, page 83-87 by Mock et al).
The unsaturated norleucines of Amanita solitaria. Chemical and pharmacological studies (Lloydia vol. 36 no. 2, 1973, page 69-73 by Chilton et al).
Beta-methylnorleucine, an antimetabolite produced by Serratia marcescens (J Antibiot, vol. 34 no. 10, 1981 page 1278-82 by Sugiura et al)
U.S. Pat. No. 6,168,912 describes various all - derivatives of amino acids for use in a multidimensional combinatorial chemical library.
Allyiglycine and crotylglycine are described in o mat of Bacteriology, vol. 148 no, 1, 1981 by Kunz et al.

SUMMARY OF THE INVENTION

The invention concerns the compound 2-amino-3-methyl-hex-5-enoic acid.
Although we use the name 2-amino-3-methyl-hex-5-enoic acid, it covers the same compound as 2-amino-3-methyl-5-hexenoic acid.
The structure of this amino acid compound in its free form is represented by Formula I:
Formula I is not to be interpreted as a Fischer projection, but rather as a compound without specification of stereochemistry.
The amino acid of Formula I comprises two chiral carbon atoms. The present invention covers the four stereoisomers of 2-amino-3-methyl-hex-5-enoic acid:
(2S,3S)-2-amino-3-methyl-hex-5-enoicacid,
(2R,3S)-2-amino-3-methyl-hex-5-enoic acid,
(2S,3R)-2-amino-3-methyl-hex-5-enoic acid, and
(2R,3R)-2-amino-3-methyl-hex-5-enoic acid.
Further, the present invention covers salts and ions of 2-amino-3-methyl-hex-5-enoic acid.
Further, the present invention covers amino protected and carboxy protected derivatives of 2-amino-3-methyl-hex-5-enoic acid.
We propose and use the name 5-Methylene-Isoleucine for 2-amino-3-methyl-hex-5-enoic acid. Accordingly, the 5-Methytene-Isoleucine side chain has the structure —CH(CH₃)CH₂CH═CH₂which could be represented
The invention also concerns use of 5-Methylene-Isoleucine for producing Bacitracins and a process for making 5-Methylene-Isoleucine
5-Methylene-Isoleucine can be used for production of Bacitracin J1, Bacitracin J2, Bacitracin J3, Bacitracin K1, Bacitracin K2, Bacitracin K3 and Bacitracin L.
The aspects of the invention may be obtained by the features as set forth in the following description of the invention and/or the appended patent claims.

DETAILED DESCRIPTION OF THE INVENTION

Some highly active Bacitracins comprise an uncommon amino acid side chain which has the following structure:
We have proposed and use the names Bacitracin J, K or L for Bacitracins comprising structure above. The structures of these Bacitracins are represented in FIG. 1A-G.

Definitions

“Bacitracins” are peptide compounds comprising the following structure (with amino acid residue numbering in superscript):
wherein X is
and, wherein R is the side chain of the amino acid residue of Isoleucine, Valine or 5-Methylene-Isoleucine;
and wherein
Y and Z are independently
the amino acid residue of
Isoleucine, Valine or 5-Methylene-Isoleucine;
and wherein
Thz is a Thiazoline ring
2′ coupled to X and 4′ coupled to the α-carbon in Leu;
and wherein
Leu is a Leucine amino acid residue
Glu is a Glutamine amino acid residue
Lys is a Lysine amino acid residue forming peptide bonds with Y and Orn while its ε-amine is coupled to the α-carboxyl group of Asparagine by a peptide bond
Orn is an Ornithine amino acid residue
Phe is a Phenylalanine amino acid residue
His is a Histidine amino acid residue
Asp is an Aspartic acid amino acid residue
Asn is an Asparagine amino acid residue forming peptide bond with Asp while its α-carboxyl group is coupled to the ε-amine of Lysine by a peptide bond.
When used in this application; “Bacitracins” is meant to embrace any compound having the primary structure above regardless of the production method. Thus, the term “Bacitracins” includes the antibiotic compounds naturally produced by Bacillus licheniformis but also in vitro produced compounds (synthetic) and semisynthetic compounds having the primary structure above. “Bacitracins” is also meant to embrace any compound having the primary structure above regardless of the charge which varies with pH. “Bacitracins” is also meant to embrace any compound having the primary structure above regardless of the stereochemistry. “Bacitracins” is also meant to embrace salts and hydrates of the compounds having the primary structure above.
“Bacitracins comprising at least one 5-Methylene-Isoleucine residue” is meant to embrace any Bacitracin comprising the structure that would be generated if a isoleucine or Valine residue(s) was substituted with 5-Methylene-Isoleucine residue(s) position 1 and/or 5 and/or 8.
When the N-terminal amino group and/or the Thiazoline ring of Bacitracins is oxidized, a substantial amount of the antibacterial activity is lost. For example the low activity compound Bacitracin F, comprises a keto-thiazole moiety instead of the amino-thiazoline moiety (J. Org. Chem., vol. 22, 1957, page 1345-1353 by Craig et al).
“Amino acid” is any compound comprising both an amine and a carboxyl group. Most proteins are built as a linear polymer of 20 different standard α-amino acids in L-configuration: Alanine, Arginine, Asparagine, .Aspartic acid, Cysteine, Glutamine, Glutamate, Phenylalanine, Glycine Histidine, Isoleucine, Lysine, Leucine, Methionine, Proline, Serine, Threonine, Tryptophan, Tyrosine and Valine.
An “Amino acid residue” is the unit in a peptide which comprises

—NH—CHR—COOH(C-terminal)

or

NH₂—CHR—CO (N-terminal)

or
NH—CHR—CO— (internal)
where R is

H Glycine,

CH₃Alanine,

OH in Serine,

CH₂SH in Cysteine,

CH(CH₃)CH₂CH₃in Isoleucine,

CH₂CH(CH₃)₂in Leucine

CH(CH₃)₂in Valine

etc.
An “Amino acid side chain” is the R-group of an “Amino acid residue”. For example, the R-group is

CH(CH)CH₂CH₃in Isoleucine,

CH₂CH(CH₃)₂in Leucine

CH(CH₂)₂in Valine

“Antibacterial activity” is any activity which
inhibits the growth, metabolism or reproduction of bacteria,
or
increases the mortality of bacteria_;or
reduces the pathogenicity of bacteria.
The “positions” of the amino acid residues in Bacitracins are numbered from the N-terminal which can be Isoleucine, Valine or 5-Methylene-Isoleucine in position 1 (the left end in all figures showing Bacitracins in this application), Hence, Lys is in position number 6 and Asn is in position number 12.
In Bacitracins, the “position 1” is special, because this amino acid residue is partly incorporated into the Thiazoline ring. Thus the amino acid residue in position 1 in Bacitracins does not comprise the usual N-terminal unit:
but comprises instead:
coupled to Thiazoline
A “composition” is any mixture comprising more than two different compounds, for example a mixture of two active pharmaceutical ingredients, or a mixture of an active pharmaceutical ingredient and one or more pharmaceutical excipients.
A “pharmaceutical composition” is any composition suitable for use in vivo. Such compositions can thus be administered cutaneously, subcutaneously, intravenously, parenterally etc.
5-Methylene-Isoleucine comprises two chiral carbon atoms which independently could be in R or S configuration.
The Bacitracins comprising at least one 5-Methylene-Isoleucine residue in position 1, 5 or 8 can be used for inhibiting unwanted bacterial growth both in vitro and in vivo. These compounds can thus have therapeutic effect if administered to an animal or a human with a bacterial infection.
The invention concerns the compound 5-Methylene-Isoleucine which could be used for production of the new Bacitracins; e.g. by in vitro synthesis of Bacitracin J1-3, K1-3 or L.
By substituting Isoleucine or Valine with 5-Methytene-Isoleucine in the methods described in J Org Chem, vol, 61 no. 12, 1996, page 3983-3986 by Lee et at or WO199747313, Bacitracins with antibacterial activity can be produced.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A shows the structure of Bacitracin with a 5-Methylene-Isoleucine residue in position 5 (=Bacitracin J1)

FIG. 1B shows the structure of Bacitracin with a 5-Methylene-Isoleucine residue in position 8 (=Bacitracin J2)

FIG. 1C shows the structure of Bacitracin with a 5-Methylene-Isoleucine residue in position 1 (=Bacitracin J3)

FIG. 1D shows the structure of Bacitracin with 5-Methylene-Isoleucine residues in position 5 and 8 (=Bacitracin K1)

FIG. 1E shows the structure of Bacitracin with 5-Methylene-Isoleucine residues in position 1 and 5 (=Bacitracin K2)

FIG. 1F shows the structure of Bacitracin with 5-Methylene-Isoleucine residues in position 1 and 8 (=Bacitracin K3)

FIG. 1G shows the structure of Bacitracin with 5-Methylene-Isoleucine residues in position 1, 5 and 8 (=Bacitracin L)

FIG. 2 shows a route tier production of 5-Methylene-Isoleucine as disclosed in the examples

The invention is defined by the claims and not by the following illustrative examples:

EXAMPLES

Example 1 (2S,3R)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-methyl-hex-5-enoic acid methyl ester and (2S,3S)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-3-methyl-hex-5-enoic acid methyl ester

Vinylmagnesium bromide in THE (1.0 M, 83.64 mL, 83.64 mmol) is added to a precooled (−10° C.) mixture of (2S,3S) and (2S,3R)-4-Iodo-N-phataloylvaline methyl ester (26.96 g, 69.68 mmol), CuCl₂(0.47 g, 3.5 mmol), dry LiCl (0.29 g, 7.0 mmol) in THF (100 mL). The reaction mixture is stirred over night at this temperature. The reaction mixture is added to saturated ammonium chloride solution (aq) (300 mL). The phases are separated and the aqueous phase is extracted with diethyl ether (3×100 mL). The combined organic phases are washed with saturated brine (100 mL), dried (MgSO₄) and the solvents are removed at reduced pressure. 10 g of the product mixture is isolated The (2S,3S) and (2S,3R) products are separated by column chromatography.

Example 2 (2S,3R)-2-Amino-3-methyl-hex-5-enoic acid

(2S,3R)-2-(1,3-Dioxo-1,3-dihydro-isoindol -2-yl)-3-methyl-hex-5-enoic acid methyl ester (2.01 g, 7.00 mmol) is dissolved in a 2:1 mixture of 6 N hydrochloric acid and glacial acetic acid (62.5 mL), and the solution is heated at reflux for 4 h. The solution is cooled to room temperature and concentrated under reduced pressure.
The product is taken up in water and the solution is filtered. The filtrate is concentrated under reduced pressure and the residue is dissolved in water, then the solution is applied to a column of amberlite IR 120 cation exchange resin (NH₄ ⁺form). The column is washed with water (2.5 L), then eluted with aqueous ammonia solution (2.5 L). The eluate is boiled until no ammonia can be detected, then concentrated under reduced pressure affording the title compound (0.5 g, 3.50 mmol).

Example 3 (2S,3S)-2-Amino-3-methyl-hex-5-enoic acid

(2S,3S)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-methyl-hex-5-enoic acid methyl ester (2.01 g, 7.00 mmol) is dissolved in a 2:1 mixture of 6 N hydrochloric acid and glacial acetic acid (62.5 mL), and the solution is heated at reflux for 4 h. The solution is cooled to room temperature and concentrated under reduced pressure.
The product is taken up in water and the solution is filtered. The filtrate is concentrated under reduced pressure and the residue is dissolved in water, then the solution is applied to a column of amberlite IR 120 cation exchange resin (NH₄ ⁺form). The column is washed with water (2.5 L), then eluted with aqueous ammonia solution (2.5 L). The eluate is boiled until no ammonia can be detected, then concentrated under reduced pressure affording the title compound (0.5 g, 150 mmol).

Example 4 (2R,3R)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-methyl-hex-5-enoic acid methyl ester and (2R,3S)-2-(1,3-dioxo -1,3-dihydro-isoindol-2-yl)-3-methyl-hex-5-enoic acid methyl ester

Vinylmagnesium bromide in THF (1.0 M, 83.64 mL, 83.64 mmol) is added to a precooled (−10° C.) mixture of (2S,3S) and (2S,3R)-4-Iodo-N-phataloyivaline methyl ester (26.96 g, 69.68 mmol), CuCl₂(0.47 g, 3.5 mmol), dry LiCl (0.29 g, 7.0 mmol) in THF (100 mL). The reaction mixture is stirred over night at this temperature. The reaction mixture is added to saturated ammonium chloride solution (aq) (300 mL). The phases are separated and the aqueous phase is extracted with diethyl ether (3×100 mL). The combined organic phases are washed with saturated brine (100 mL), dried (MgSO₄) and the solvents are removed at reduced pressure. 10 g of the product mixture is isolated. The (2R,3S) and (2R,3R) products are separated by column chromatography.

Example 5 (2R,3R)-2-Amino-3-methyl-hex-5-enoic acid

(2R,3R)-2-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-3-methyl-hex-5-enoic acid methyl ester (2.01 g, 7.00 mmol) is dissolved in a 2:1 mixture of 6 N hydrochloric acid and glacial acetic acid (62.5 mL), and the solution is heated at reflux for 4 h. The solution is cooled to room temperature and concentrated under reduced pressure.
The product is taken up in water and the solution is filtered. The filtrate is concentrated under reduced pressure and the residue is dissolved in water, then the solution is applied to a column of amberlite IR 120 cation exchange resin (NH₄ ⁺form). The column is washed with water (2.5 then eluted with aqueous ammonia solution (2.5 L). The eluate is boiled until no ammonia can be detected, then concentrated under reduced pressure affording the title compound (0.5 g, 3.50 mmol).

Example 6 (2R,3S)-2-Amino-3-methyl-hex-5-enoic acid

(2R,3S)-1,3-Dioxo-1,3-dihydro-hex-5-enoic acid methyl ester (2.01 g, 7.00 mmol ) is dissolved in a 2:1 mixture of 6 N hydrochloric acid and glacial acetic acid (62.5 mL), and the solution is heated at reflux for 4 h. The solution is cooled to room temperature and concentrated under reduced pressure. The product is taken up in water and the solution is filtered. The filtrate is concentrated under reduced pressure and the residue is dissolved in water, then the solution is applied to a column of amberlite IR 120 cation exchange resin (NH₄ ⁺form). The column is washed with water (2.5 L), then eluted with aqueous ammonia solution (2.5 L). The eluate is boiled until no ammonia can be detected, then concentrated under reduced pressure affording the title compound (0.5 g, 3.50 mmol).

Claims

1. A peptide comprising a 2-amino-3-methyl-hex-5-enoic acid residue having the following side chain

wherein the peptide is not a bacitracin.

2. A composition comprising 2-amino-3-methyl-hex-5-enoic acid.

3. The composition of claim 2, wherein the 2-amino-3-methyl-hex-5-enoic acid is in the (2S,3S) configuration.

4. The composition of claim 2, wherein the 2-amino-3-methyl-hex-5-enoic acid is in the (2R,3S) configuration.

5. The composition of claim 2, wherein the 2-amino-3-methyl-hex-5-enoic acid is in the (2S,3R) configuration.

6. The composition of claim 2, wherein the 2-amino-3-methyl-hex-5-enoic acid is in the (2R,3R) configuration

7. The composition of claim 2, in the form of a pharmaceutical composition comprising a pharmaceutically acceptable excipient.